- Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study
Alessandro Parisi et al, 2019, Journal of Cancer Research and Clinical Oncology CrossRef - Primary versus secondary antiemetic prophylaxis with NK1 receptor antagonists in patients affected by gastrointestinal malignancies and treated with a doublet or triplet combination regimen including oxaliplatin and/or irinotecan plus fluoropyrimidines: A propensity score matched analysis
Alessandro Parisi et al, 2022, Frontiers in Oncology CrossRef